ngµç×ÓÓÎÏ·ÐÂÎÅÍøÑ¶£¨Í¨Ñ¶Ô±²Ì¾²£©2022Äê5ÔÂ12ÈÕ£¬£¬ngµç×ÓÓÎÏ·ÖÐɽҽѧԺÑÕ¹âÃÀ½ÌÊÚÍŶÓÔÚÖ÷Òª×ÅÃû¿ÆÑ§ÆÚ¿¯Molecular Therapy£¨ÊµÊ±IF=12.758£©ÔÓÖ¾ÔÚÏß½ÒÏþÌâΪ¡°Overcoming resistance to oncolytic virus M1 by targeting PI3K-¦Ã in tumor associated myeloid cells¡±µÄArticleÑо¿ÂÛÎÄ¡£¸ÃÑо¿ÅжÏÁËÖ×ÁöÏà¹ØËèϵϸ°û£¨TAMCs£©ºÍPI3K-¦ÃÊÇÄÑÖÎÐÔ¶ñÐÔÖ×Áö·´¿¹ÐÂÐÍÈÜÁö²¡¶¾M1£¨OVM£©ÖÎÁƵÄϸ°ûºÍ·Ö×Ó»úÖÆ£¬£¬²¢Öƶ©È¥³ý·´¿¹Õ½ÂÔ£¬£¬¸ß±ÈÀýÖÎÓúÁ˶àÖÖÄÑÖÎÐÔÍíÆÚ°©Ö¢£¨°üÀ¨½áÖ±³¦°©¡¢¡¢¡¢ÒÈÏÙ°©ºÍÈýÒõÈéÏÙ°©£©¡£
Æù½ñΪֹ£¬£¬ÈκÎÒ»ÖÖ°©Ö¢ÖÎÁÆÒ©Îï»òÔç»òÍí¶¼»á±¬·¢¿¹Ò©ÐÔ£¬£¬ÑÕ¹âÃÀ½ÌÊÚÍŶÓǰհÐԵؿªÕ¹ÁËδÀ´¿ÉÄܶÔOVM±¬·¢¿¹Ò©ÐԵĻúÀíºÍÒªÁì¡£ÔÚ±¾ÏîÑо¿ÖУ¬£¬Ñо¿ÍŶÓÊ×ÏÈÈ·Ö¤Á˲¿·ÖÌåÍâ¶ÔOVM¸ß¶ÈÃô¸ÐµÄÖ×Áöϸ°ûÖêÔÚÌåÄÚÈ´·´¿¹ OVM ÖÎÁÆ¡£½øÒ»²½µÄÑо¿·¢Ã÷£¬£¬Ö×Áö΢ÇéÐÎÖеÄËèϵϸ°û£¨¼´Ö×ÁöÏà¹ØËèϵϸ°ûTAMCs£©ÊÇÏÞÖÆOVMÁÆÐ§µÄÃâÒßÒÖÖÆÒòËØ£¬£¬ÇÒɾ³ýËèϵϸ°ûÄÜ´ó·ùÌá¸ßOVMµÄÁÆÐ§¡£ÓÐȤµÄÊÇ£¬£¬ÔÚ¶ÔOVMÖÎÁÆÃô¸ÐºÍ·´¿¹µÄÖ×ÁöÄ£×ÓÖУ¬£¬OVM´¦Àí¾ùÉϵ÷TAMCsµÄ½þÈ󣬣¬ÇÒOVM´¦Àí¼Ó¾çÁËTAMCsµÄÃâÒßÒÖÖÆ±íÐÍ¡£×ªÂ¼×é²âÐòºÍÑéÖ¤ÐÔʵÑé֤ʵ£¬£¬OVMÓÕµ¼Ö×Áöϸ°ûÉøÍ¸Ï¸°ûÒò×ÓIL-6£¬£¬IL-6¼¤»îTAMCsÖеÄPI3K-¦Ã£¨¸ÃPI3KÑÇÐͽö±£´æÓÚËèϵϸ°ûÖУ©Ðźţ¬£¬½øÒ»²½Ôö½øTAMCsǨáãÖÁÖ×Áö²¿Î»²¢¼Ó¾çTAMCs¶Ôϸ°û¶¾ÐÔCD8+TÁܰÍϸ°ûµÄÒÖÖÆ×÷Óá£ÔÚ¶àÖÖÄÑÖÎÐÔ¶ñÐÔÖ×ÁöÄ£×ÓÖУ¬£¬°ÐÏòÒÖÖÆPI3K-¦ÃïÔÌÖ×Áö½þÈóËèϵϸ°ûµÄ±ÈÀý£¬£¬Å¤×ªÆäÃâÒßÒÖÖÆ±íÐÍ£¬£¬½ø¶øÏÔÖøÔöÇ¿OVMµÄÁÆÐ§¡£½øÒ»²½µØ£¬£¬OVMÁªºÏ PI3K-¦ÃÒÖÖÆ¼ÁºÍÃâÒß¼ì²éµã×è¶ÏÄÜÖÎÓú33.3%µÄÈýÒõÈéÏÙ°©¡¢¡¢¡¢83.3%µÄ½áÖ±³¦°©ºÍ62.5%µÄÒÈÏÙ°©¡£ÔÚÒÈÏÙ°©ÖÎÓúÊóÖÐÔٴνÓÖÖ10±¶ÓÚÊ״νÓÖÖϸ°ûÊýÄ¿µÄÒÈÏÙ°©Ï¸°û£¬£¬Ö×Áö²»¿ÉÉú³¤£¬£¬ËµÃ÷ÖÎÓúÊó·ºÆðÁË¿¹Ö×ÁöÃâÒßÓ°Ïó¡£×ÛÉÏËùÊö£¬£¬¸ÃÑо¿ÅжÏÁËÖ×Áö΢ÇéÐÎÖÐÏÞÖÆOVM ÁÆÐ§µÄÃâÒßÒÖÖÆÏ¸°ûºÍ·Ö×Ó»úÖÆ£¬£¬²¢ÌṩÁËͨ¹ýɨ³ýËèϵÃâÒßÒÖÖÆÇ¿»¯OVMÈÜÁöЧӦµÄ¶àÖÖÓÃÒ©Õ½ÂÔ£¬£¬Îª½â¾öÈÜÁö²¡¶¾Ñо¿ÁìÓòÖз´¿¹ÐÔºÍÁÆÐ§ÏÞÖÆÕâÒ»¹²ÐÔÎÊÌâÌṩÁËÑо¿·¶Ê½¡£

ͼע£º£º£ºÐÂÐÍÈÜÁö²¡¶¾M1ÖÎÁÆ·´¿¹µÄϸ°ûºÍ·Ö×Ó»úÖÆ
ngµç×ÓÓÎÏ·ÖÐɽҽѧԺÑÕ¹âÃÀ½ÌÊÚÍŶӵIJ©Ê¿ºóÁõÑóΪ±¾ÂÛÎĵĵÚÒ»×÷Õߣ¬£¬²Ì¾²¸±Ñо¿Ô±ºÍÁÖÔ°¸±½ÌÊÚΪÅäºÏͨѶ×÷Õß¡£±¾ÎÄ»ñµÃÁ˹ú¼ÒÖØµãÑз¢ÍýÏë¡¢¡¢¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ðÃæÉÏÏîÄ¿¡¢¡¢¡¢¹ã¶«Ê¡×ÔÈ»¿ÆÑ§»ù½ð¡¢¡¢¡¢Öйú²©Ê¿ºó¿ÆÑ§»ù½ðºÍngµç×ÓÓÎÏ·ÖÐɽҽѧԺ-Á¥ÊôµÚÒ»Ò½ÔºÏȽøÒ½Ñ§¿ÆÑ§ÊÖÒÕÑо¿ÖÐÐĵÄÖ§³Ö¡£
ÂÛÎÄÁ´½Ó£º£º£ºhttps://www.sciencedirect.com/science/article/abs/pii/S1525001622003069